首页> 外文OA文献 >The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice

【2h】

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice

机译：非小细胞肺癌中获得抗EGFR药物的抗性的机制与T790M突变无关及其在临床实践中的重要性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
E. V. Karabina; L. N. Lubchenko; M. M. Davydov;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. Continuation of gefitinib plus chemotherapy prolongs progression- free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [J] . Ting Ding, Fei Zhou, Xiaoxia Chen, Journal of Thoracic Disease . 2017,第9期

机译：Gefitinib Plus化疗的延续延长了在未经T790M突变的情况下获得对吉替尼的抗性的先进非小细胞肺癌患者的无进展生存
3. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations [J] . HataA., KatakamiN., YoshiokaH., Cancer: A Journal of the American Cancer Society . 2013,第24期

机译：对表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的非小细胞肺癌患者的活检：T790M突变阳性和突变阴性人群的比较
4. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations [J] . HataA., KatakamiN., YoshiokaH., Cancer: A Journal of the American Cancer Society . 2013,第24期

机译：非小细胞肺癌患者的抗性对表皮生长因子受体 - 酪氨酸激酶抑制剂的预曲线：T790M突变阳性和突变阴性群体的比较
5. Clinical Significance of VEGF,EGFR and BRCA-1 Expression in Non-Small Cell Lung Cancer [C] . Wang Linhui, Li Yu 5th International Conference on Bioinformatics and Biomedical Engineering . 2011

机译：VEGF，EGFR和BRCA-1在非小细胞肺癌中的表达及其临床意义
6. Crippling Rapid Evolution of Metastasis and Drug Resistance in A549 Non-Small Cell Lung Cancer Cells with the Clinically Relevant HSP90 Inhibitor AUY922 [D] . Bacon, Nickolas. 2021

机译：临床相关的HSP90抑制剂Auy922，A549非小细胞肺癌细胞转移和耐药性快速演变和耐药性的快速演变
7. Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation [O] . Chong-Kin Liam, Mau-Ern Poh, Yong-Sheng Liam 2019

机译：对T790M突变引起的酪氨酸激酶抑制剂获得性耐药的表皮生长因子受体突变型非小细胞肺癌患者临床特征对奥西替尼治疗疗效的影响
8. Clinical Significance of T790M After Acquiring Resistance to Gefitinib or Erlotinib in Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Gene Mutation [O] . Kazutoshi Isobe, Yoshinobu Hata, Keita Sato, 2012

机译：在表皮生长因子受体基因突变的非小细胞肺癌患者中抗吉维替尼或奥罗替尼抗性后T790m的临床意义

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice

著录项

引文网络

相似文献

相关主题

期刊订阅